To study time-of-day infusion of immunotherapy may impact outcomes in advanced non-small cell lung cancer patients (NSCLC)
Latest Information Update: 18 Jul 2022
At a glance
- Drugs Atezolizumab (Primary) ; Nivolumab (Primary) ; Pembrolizumab (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
Most Recent Events
- 18 Jul 2022 New trial record
- 07 Jun 2022 Preliminary analysis presented at the 58th Annual Meeting of the American Society of Clinical Oncology